*Naomi Hasegawa1, Yuka Yasuda2,1, Norio Yasui-Furukori3, Hikaru Hori4, Kayo Ichihashi5, Yoshikazu Takaesu6, Hitoshi Iida4, Hiroyuki Muraoka7, Fumitoshi Kodaka8, Junya Matsumoto1, Kenichiro Miura1, Ken Inada7, Koichiro Watanabe9, Ryota Hashimoto1
(1. Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan, 2. Life Grow Brilliant Mental Clinic, Medical Corporation Foster, Osaka, Japan, 3. Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan, 4. Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, 5. Department of Neuropsychiatry, University of Tokyo Hospital, Tokyo, Japan, 6. Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan, 7. Department of Psychiatry, Kitasato University, School of Medicine, Kanagawa, Japan, 8. Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan, 9. Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan)
Keywords:Clinical Practice Guideline, Major Depressive Disorder, Schizophrenia
Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.